Date: 2015-03-03
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Acetylon Pharmaceuticals (USA - MA)
Product: citarinostat (ACY-241)
Action
mechanism: histone deacetylase inhibitor/HDAC . Citarinostat, also known as ACY-241, is a elective and orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity.
Disease: multiple myeloma
Therapeutic area: Cancer - Oncology
Country: France, Germany, Greece, Ireland, Spain, Italy, USA
Trial
details: This is a phase 1a/1b, multicenter, single-arm, open-label, dose escalation study to determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary antitumor activity of ACY-241 for oral administration as monotherapy and in combination therapy with orally administered pomalidomide and low-dose dexamethasone in eligible patients with relapsed or relapsed-and-refractory multiple myeloma. ( NCT02400242)
Latest
news: * On March 3, 2015, a Phase 1trial sponsored by Acetylon Pharmaceuticals was published on the NIH website ClinicalTrials.gov for ACY-241 alone and in combination with pomalidomide and dexamethasone in multiple myeloma and is currently recruiting participants.
